M a i n r e s u l t s
The Table shows the main results. Differences between groups were also analyzed according to very high HbA 1c (> 9.5% to 12%) (superiority) and moderately high HbA 1c (8% to 9.5%) (noninferiority). Patients in the INH group had lower lung function than did those in the metformin group (FEV 1 : difference in adjusted mean change −0.07 L, 95% CI −0.12 to −0.03; FVC: difference −0.06 L, CI −0.11 to −0.01).
C o n c l u s i o n
Patients with type 2 diabetes mellitus that was poorly controlled with sulfonylurea monotherapy had better glycemic control but more hypoglycemic events after the addition of premeal inhaled insulin than did those after the addition of metformin. Clinical impact ratings: GIM/FP/GP ★★★★★★★ Endocrinology ★★★★★✩✩ C o m m e n t a r y
Patients' inability to modify their lifestyle for a disorder attributed to sedentary lifestyle, limited long-term efficacy of current antihyperglycemic medications, and objection to the use of such medications as insulin may contribute to poor glycemic control in type 2 diabetes. Poor glycemic control may be caused by an unacceptable route of medication (e.g., parenteral) and fear of hypoglycemia. Therefore, inhaled insulin preparations are an interesting addition to the therapeutic armamentarium.
Limitations of the study by Barnett and colleagues include different titration schedules for the 2 groups and more contact between providers and patients in the INH group, lack of blinding, and important loss to follow-up.
Where do we stand with regard to treatment of type 2 diabetes? Monotherapy choices include metformin, sulfonylureas, thiazolidinediones, meglitinides, and α-glucosidase inhibitors. When a second medication is required, exenatide, long-and intermediate-acting insulin preparations, and now INH are options. Patients and clinicians can choose combinations based on comorbid conditions and patient preference. The combination of metformin and exenatide seems most attractive, given its efficacy, safety (no hypoglycemia), and favorable weight changes (1) . INH use in practice will require considering additional training of providers to instruct patients on its use, unknown long-term effects on lung function, unknown significance of insulin antibodies, unknown relation of insulin antibodies to hypoglycemic episodes, and limited portability of the inhalation device (2) .
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